• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why AERWINS Technologies Shares Are Trading Higher By Around 90%; Here Are 20 Stocks Moving Premarket

    10/2/23 8:11:18 AM ET
    $ACAQ
    $AWIN
    $BITF
    $BNOX
    Blank Checks
    Finance
    Aerospace
    Industrials
    Get the next $ACAQ alert in real time by email

    Gainers

    AERWINS Technologies Inc. (NASDAQ:AWIN) shares rose 90.2% to $0.2297 in pre-market trading. Aerwins Technologies is considering strategic alternatives for non-core operations including, not limited to possible sale/other disposition of assets.

    RVL Pharmaceuticals plc (NASDAQ:RVLP) shares rose 24.5% to $0.1078 in pre-market trading after gaining over 10% on Friday.

    Better Choice Company Inc. (NYSE:BTTR) shares gained 21.4% to $0.1505 in pre-market trading after gaining 5% on Friday.

    Bionomics Limited (NASDAQ:BNOX) shares rose 21.1% to $3.27 in pre-market trading after falling 20% on Friday.

    Athena Consumer Acquisition Corp. (NASDAQ:ACAQ) shares surged 20.4% to $8.98 in pre-market trading after falling 20% on Friday.

    EMCORE Corporation (NASDAQ:EMKR) rose 19.7% to $0.5691 in pre-market trading after falling 5% on Friday.

    Syndax Pharmaceuticals, Inc.. (NASDAQ:SNDX) gained 13.6% to $16.50 in pre-market trading. Syndax will share topline results from the pivotal AUGMENT-101 trial in patients with relapsed/refractory KMT2Ar acute leukemia on Oct. 2, 2023.

    Bitfarms Ltd. (NASDAQ:BITF) shares climbed 13.1% to $1.21 in pre-market trading.

    Femasys Inc. (NASDAQ:FEMY) rose 11.1% to $3.31 in pre-market trading. Femasys shares jumped 46% on Friday after HC Wainwright maintained a Buy rating on the stock and raised its price target from $5 to $13.

    Oragenics, Inc. (NYSE:OGEN) shares jumped 10.4% to $3.28 in pre-market trading after the company entered into agreement with Lantern Bioworks for replacement-therapy assets.

    Losers

    SmileDirectClub, Inc. (NASDAQ:SDC) fell 64.1% to $0.1489 in pre-market trading. SmileDirectClub filed for bankruptcy just a few years after its remarkable $1.35 billion IPO.

    Intelligent Bio Solutions Inc. (NASDAQ:INBS) fell 23.8% to $0.80 in pre-market trading after declining 7% on Friday.

    Context Therapeutics Inc. (NASDAQ:CNTX) shares fell 15.8% to $1.27 in pre-market trading after jumping around 19% on Friday.

    Nexalin Technology, Inc. (NASDAQ:NXL) fell 14.7% to $0.3752 in pre-market trading. On Sept. 21, 2023, Marilyn Elson submitted her resignation as CFO Of Nexalin Technology.

    ReShape Lifesciences Inc. (NASDAQ:RSLS) shares fell 14.2% to $0.2901 in pre-market trading after declining 23% on Friday. ReShape Lifesciences reported pricing of $3.0 million public offering.

    Brooge Energy Limited (NASDAQ:BROG) fell 9.8% to $5.02 in pre-market trading. Brooge Energy said revenue jumped 122% year-over-year to $62.9 million for the first six months ending June 30, 2023.

    Danaher Corporation (NYSE:DHR) shares fell 9.6% to $224.32 in pre-market trading. Danaher said it completed separation of Veralto Corporation.

    Siyata Mobile Inc. (NASDAQ:SYTA) fell 9.6% to $2.55 in pre-market trading.

    Grom Social Enterprises Inc (NASDAQ:GROM) fell 8% to $1.26 in pre-market trading. Grom Social recently priced a $3 million offering.

    Bolt Biotherapeutics Inc (NASDAQ:BOLT) fell 7.7% to $0.96 in pre-market. The FDA recently granted Orphan Drug Designation for Bolt Biotherapeutics' BDC-1001 for gastric cancer, including gastroesophageal junction cancer.

    Now Read This: Nio, Li Auto And 3 Stocks To Watch Heading Into Monday

    Get the next $ACAQ alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACAQ
    $AWIN
    $BITF
    $BNOX

    CompanyDatePrice TargetRatingAnalyst
    Bitfarms Ltd.
    $BITF
    1/27/2026$3.00Outperform → Mkt Perform
    Keefe Bruyette
    Danaher Corporation
    $DHR
    12/9/2025$265.00Buy
    Goldman
    Danaher Corporation
    $DHR
    12/2/2025$270.00Overweight
    Morgan Stanley
    Femasys Inc.
    $FEMY
    11/20/2025$6.50Buy
    Laidlaw
    Bolt Biotherapeutics Inc.
    $BOLT
    10/20/2025$7.00Buy
    H.C. Wainwright
    Syndax Pharmaceuticals Inc.
    $SNDX
    10/16/2025$40.00Buy
    H.C. Wainwright
    Danaher Corporation
    $DHR
    10/8/2025$220.00Buy → Neutral
    Rothschild & Co Redburn
    Context Therapeutics Inc.
    $CNTX
    9/18/2025$5.00Buy
    Guggenheim
    More analyst ratings

    $ACAQ
    $AWIN
    $BITF
    $BNOX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Bitfarms downgraded by Keefe Bruyette with a new price target

    Keefe Bruyette downgraded Bitfarms from Outperform to Mkt Perform and set a new price target of $3.00

    1/27/26 8:40:33 AM ET
    $BITF
    Finance: Consumer Services
    Finance

    Goldman initiated coverage on Danaher with a new price target

    Goldman initiated coverage of Danaher with a rating of Buy and set a new price target of $265.00

    12/9/25 8:43:56 AM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    Morgan Stanley initiated coverage on Danaher with a new price target

    Morgan Stanley initiated coverage of Danaher with a rating of Overweight and set a new price target of $270.00

    12/2/25 8:25:25 AM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    $ACAQ
    $AWIN
    $BITF
    $BNOX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Gagnon Benjamin

    4 - Keel Infrastructure Corp. (0001812477) (Issuer)

    4/6/26 5:01:08 PM ET
    $BITF
    Finance: Consumer Services
    Finance

    SEC Form 4 filed by Ammann Marc-Andre

    4 - Keel Infrastructure Corp. (0001812477) (Issuer)

    4/6/26 4:59:33 PM ET
    $BITF
    Finance: Consumer Services
    Finance

    SEC Form 4 filed by Wilson Liam Daniel

    4 - Keel Infrastructure Corp. (0001812477) (Issuer)

    4/6/26 4:57:57 PM ET
    $BITF
    Finance: Consumer Services
    Finance

    $ACAQ
    $AWIN
    $BITF
    $BNOX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $ACAQ
    $AWIN
    $BITF
    $BNOX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    $ACAQ
    $AWIN
    $BITF
    $BNOX
    SEC Filings

    View All

    Syndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026

    NEW YORK, April 24, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its first quarter 2026 financial results and provide a business update on Thursday, April 30, 2026. In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 4:30 p.m. ET on Thursday, April 30, 2026. The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website. Alternatively, the conference call may be accessed through the following: Confere

    4/24/26 7:00:00 AM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Danaher Announces Pricing of Euro-Denominated Senior Notes Offering

    WASHINGTON, April 22, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) ("Danaher") announced today that it has priced an offering of the following euro-denominated senior notes (the "Offering"): €500,000,000 principal amount of floating rate senior notes due 2028 at an offering price of 100.000% of the principal amount;€750,000,000 principal amount of 3.250% senior notes due 2030 at an offering price of 99.934% of the principal amount;€750,000,000 principal amount of 3.625% senior notes due 2034 at an offering price of 99.918% of the principal amount; and€1,000,000,000 principal amount of 4.000% senior notes due 2038 at an offering price of 99.953% of the principal amount (collectively, t

    4/22/26 7:15:00 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    Femasys Launches FemaSeed® Complete for OB/GYNs at ACOG 2026

    ATLANTA, April 22, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today the commercial launch of FemaSeed Complete, a comprehensive fertility solution that enables OB/GYNs to perform first-line insemination entirely within their own practices. An estimated 10 million women in the United States experience infertility, yet fewer than half access care, and only a very small percentage ultimately undergo IVF. At the same time, U.S. fertility rates declined again in 2025 to a record low, underscoring the growing need for ear

    4/22/26 9:00:00 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    FDA Approval for REVUFORJ issued to SYNDAX PHARMACEUTICALS INC

    Submission status for SYNDAX PHARMACEUTICALS INC's drug REVUFORJ (ORIG-1) with active ingredient REVUMENIB has changed to 'Approval' on 11/15/2024. Application Category: NDA, Application Number: 218944, Application Classification: Type 1 - New Molecular Entity

    11/18/24 9:22:42 AM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Danaher Corporation

    424B5 - DANAHER CORP /DE/ (0000313616) (Filer)

    4/23/26 4:15:02 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    SEC Form FWP filed by Danaher Corporation

    FWP - DANAHER CORP /DE/ (0000313616) (Subject)

    4/22/26 4:34:46 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    Nexalin Technology Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Nexalin Technology, Inc. (0001527352) (Filer)

    4/22/26 4:30:18 PM ET
    $NXL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ACAQ
    $AWIN
    $BITF
    $BNOX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President, CEO and CFO Quinn William P. bought $576 worth of shares (125 units at $4.61), increasing direct ownership by 6% to 2,313 units (SEC Form 4)

    4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)

    2/4/26 4:32:38 PM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Senior VP, Finance and PAO Nemec Sarah bought $576 worth of shares (125 units at $4.61), increasing direct ownership by 10% to 1,415 units (SEC Form 4)

    4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)

    2/4/26 4:32:00 PM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Senior VP, Finance and PAO Nemec Sarah was granted 23,000 shares and bought $686 worth of shares (125 units at $5.49), increasing direct ownership by 2,827% to 23,943 units (SEC Form 4)

    4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)

    10/24/25 7:19:22 PM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAQ
    $AWIN
    $BITF
    $BNOX
    Leadership Updates

    Live Leadership Updates

    View All

    Neogen® Corporation Announces Appointment of Jennifer Evans Stacey as Chief Legal & Compliance Officer and Board Secretary

    Neogen Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, today announced the appointment of Jennifer Evans Stacey as Chief Legal & Compliance Officer and Board Secretary. Ms. Stacey is an accomplished chief legal and compliance officer and board secretary with extensive experience in the life sciences industry. She has served more than 10 years as a public company chief legal and compliance officer and board secretary, as well as five years as a public company board member. Over her more than 25-year career, she has led legal, compliance, government relations, corporate communications and human resources functions, operating in complex, fast-moving environments.

    4/8/26 8:00:00 AM ET
    $CNTX
    $NEOG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    Femasys Appoints John Canning as Chief Operating Officer to Drive Operational Execution and Advance Commercial Growth

    ATLANTA, April 01, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today the appointment of John Canning as Chief Operating Officer. Mr. Canning is an accomplished medical device executive with more than 25 years of experience leading global operations and technology organizations within complex medical device companies. He brings a track record of scaling organizations, advancing product pipelines, and driving operational excellence across key functions to support commercial growth and product adoption. Prior to joining

    4/1/26 9:00:00 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors

    ATLANTA, March 18, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today the appointment of Kenneth D. Eichenbaum, M.D., M.S.E., to its Board of Directors. Dr. Eichenbaum is a board-certified anesthesiologist with clinical affiliations at Corewell Health William Beaumont University Hospital and Trinity Health Oakland Hospital, bringing deep clinical expertise and strategic insight developed through more than 20 years of evaluating biotechnology and medical device companies and advising investment firms. He completed a fel

    3/18/26 9:00:00 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    $ACAQ
    $AWIN
    $BITF
    $BNOX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by EMCORE Corporation

    SC 13G - EMCORE CORP (0000808326) (Subject)

    11/18/24 4:55:14 PM ET
    $EMKR
    Semiconductors
    Technology

    Amendment: SEC Form SC 13G/A filed by Oragenics Inc.

    SC 13G/A - ORAGENICS INC (0001174940) (Subject)

    11/14/24 7:29:57 PM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Siyata Mobile Inc.

    SC 13G/A - Siyata Mobile Inc. (0001649009) (Subject)

    11/14/24 7:28:44 PM ET
    $SYTA
    Telecommunications Equipment
    Telecommunications

    $ACAQ
    $AWIN
    $BITF
    $BNOX
    Financials

    Live finance-specific insights

    View All

    Syndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026

    NEW YORK, April 24, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its first quarter 2026 financial results and provide a business update on Thursday, April 30, 2026. In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 4:30 p.m. ET on Thursday, April 30, 2026. The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website. Alternatively, the conference call may be accessed through the following: Confere

    4/24/26 7:00:00 AM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Danaher Reports First Quarter 2026 Results

    WASHINGTON, April 21, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) today announced results for the first quarter 2026.  All results in this release reflect only continuing operations and period-to-period comparisons are year-over-year unless otherwise noted. Key First Quarter 2026 ResultsNet earnings were $1.0 billion, or $1.45 per diluted common share.Non-GAAP adjusted diluted net earnings per common share grew 9.5% to $2.06.Revenues increased 3.5% year-over-year to $6.0 billion and non-GAAP core revenue increased 0.5% year-over-year.Operating cash flow was $1.3 billion and non-GAAP free cash flow was $1.1 billion.Strong Q1 earnings performance enabling increased full year 2026 adju

    4/21/26 6:00:00 AM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    Join Nexalin's Exclusive Live Investor Webinar and Q&A Session on April 21

    ORLANDO, FL, April 14, 2026 (GLOBE NEWSWIRE) -- RedChip Companies will host an investor webinar on April 21, 2026, at 4:15 p.m. ET with Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW)). The exclusive event will feature Nexalin's CEO Mark White, who will provide an in-depth overview of the company's differentiated approach to mental healthcare through its proprietary, non-invasive Deep Intracranial Frequency Stimulation (DIFS™) technology. White will highlight Nexalin's expanding body of clinical evidence—including peer-reviewed studies and collaborations with leading institutions such as UC San Diego—while outlining progress across its next-generation product portfolio, including the Gen-3 H

    4/14/26 8:30:00 AM ET
    $NXL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care